Protocol Ledger

NCT04985604 · Phase II · TERMINATED

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Interventional Phase II clinical trial protocol NCT04985604 sponsored by Day One Biopharmaceuticals in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-07-15 Enrollment: 23 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04985604
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)23 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04985604
Protocol FieldVerified Registry Value
NCT IdentifierNCT04985604
Consolidated Lead SponsorDay One Biopharmaceuticals
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment23 participants (ACTUAL)
Registered Start Date2021-07-15
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI